Raymond James & Associates’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-667
| Closed | -$32K | – | 4013 |
|
|
2022
Q3 | $32K | Sell |
667
-372
| -36% | -$22.1K | ﹤0.01% | 3751 |
|
|
2022
Q2 | $59K | Sell |
1,039
-161
| -13% | -$10.2K | ﹤0.01% | 3770 |
|
|
2022
Q1 | $97K | Sell |
1,200
-701
| -37% | -$104K | ﹤0.01% | 3825 |
|
|
2021
Q4 | $385K | Sell |
1,901
-204
| -10% | -$44.3K | ﹤0.01% | 3284 |
|
|
2021
Q3 | $567K | Buy |
2,105
+264
| +14% | +$63.5K | ﹤0.01% | 2975 |
|
|
2021
Q2 | $474K | Sell |
1,841
-96
| -5% | -$26.6K | ﹤0.01% | 3117 |
|
|
2021
Q1 | $581K | Buy |
1,937
+151
| +8% | +$47K | ﹤0.01% | 2907 |
|
|
2020
Q4 | $455K | Buy |
1,786
+8
| +0.4% | +$2.07K | ﹤0.01% | 2879 |
|
|
2020
Q3 | $442K | Sell |
1,778
-26
| -1% | -$8.18K | ﹤0.01% | 2718 |
|
|
2020
Q2 | $627K | Buy |
1,804
+94
| +5% | +$29.3K | ﹤0.01% | 2445 |
|
|
2020
Q1 | $458K | Sell |
1,710
-32
| -2% | -$9.9K | ﹤0.01% | 2481 |
|
|
2019
Q4 | $564K | Buy |
1,742
+107
| +7% | +$31K | ﹤0.01% | 2643 |
|
|
2019
Q3 | $447K | Sell |
1,635
-2,378
| -59% | -$872K | ﹤0.01% | 2727 |
|
|
2019
Q2 | $2.14M | Buy |
4,013
+1,152
| +40% | +$578K | ﹤0.01% | 1760 |
|
|
2019
Q1 | $1.44M | Buy |
2,861
+73
| +3% | +$43.3K | ﹤0.01% | 1980 |
|
|
2018
Q4 | $1.38M | Sell |
2,788
-1,073
| -28% | -$648K | ﹤0.01% | 1885 |
|
|
2018
Q3 | $3.53M | Sell |
3,861
-655
| -15% | -$559K | 0.01% | 1440 |
|
|
2018
Q2 | $3.31M | Sell |
4,516
-1,627
| -26% | -$1.88M | 0.01% | 1435 |
|
|
2018
Q1 | $9.79M | Sell |
6,143
-2,858
| -32% | -$3.68M | 0.02% | 790 |
|
|
2017
Q4 | $8.06M | Buy |
9,001
+474
| +6% | +$280K | 0.01% | 878 |
|
|
2017
Q3 | $3.07M | Buy |
8,527
+64
| +0.8% | +$20K | 0.01% | 1344 |
|
|
2017
Q2 | $2.48M | Buy |
8,463
+679
| +9% | +$196K | 0.01% | 1427 |
|
|
2017
Q1 | $2.74M | Sell |
7,784
-2,080
| -21% | -$468K | 0.01% | 1346 |
|
|
2016
Q4 | $1.81M | Buy |
9,864
+2,404
| +32% | +$489K | ﹤0.01% | 1549 |
|
|
2016
Q3 | $1.92M | Buy |
7,460
+1,809
| +32% | +$466K | 0.01% | 1482 |
|
|
2016
Q2 | $1.21M | Buy |
5,651
+138
| +3% | +$30.8K | ﹤0.01% | 1634 |
|
|
2016
Q1 | $1.14M | Buy |
5,513
+161
| +3% | +$30.9K | ﹤0.01% | 1613 |
|
|
2015
Q4 | $1.35M | Buy |
5,352
+215
| +4% | +$44.2K | ﹤0.01% | 1468 |
|
|
2015
Q3 | $845K | Buy |
5,137
+106
| +2% | +$18.8K | ﹤0.01% | 1680 |
|
|
2015
Q2 | $944K | Buy |
5,031
+764
| +18% | +$131K | ﹤0.01% | 1767 |
|
|
2015
Q1 | $704K | Buy |
4,267
+2,727
| +177% | +$560K | ﹤0.01% | 1869 |
|
|
2014
Q4 | $358K | Buy |
+1,540
| New | +$329K | ﹤0.01% | 2065 |
|
Other funds holding NKTR
Raymond James & Associates's NKTR Position: Q4 2022 in Review
Raymond James & Associates sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 667 shares — an estimated $32K sold.
Raymond James & Associates first reported a position in NKTR in Q4 2014 and held it in 32 quarters. The position peaked at $9.79M in Q1 2018. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.
- Raymond James & Associates reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
- Raymond James & Associates sold 667 Nektar Therapeutics shares in Q4 2022, an estimated $32K.
- Raymond James & Associates first reported a position in Nektar Therapeutics in Q4 2014 and held it in 32 quarters.
- Raymond James & Associates's Nektar Therapeutics position peaked at $9.79M in Q1 2018.
- 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.
Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.